TMDXTransMedics Group, Inc.
$77.81-36% 1Y
$77.81
$62.0452 weeks$150.42
The financials
TransMedics Group, Inc. by the numbers
TransMedics Group, Inc. (TMDX) reported revenue of $190M in Q2 2026 (quarter ended Jun 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 60% and net income of $15M (7.7% of revenue). For the full year FY2025, revenue was $605M (+37% year on year) and net income $190M. Its largest product in Q2 2026 was Liver Product at $148M, 80% of the disclosed total, well ahead of Heart Product at 18%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $190M | $157M | +21% |
| Gross profit | $113M | $97M | +17% |
| Operating income | $24M | $37M | −35% |
| Net income | $15M | $35M | −58% |
| Diluted EPS | $0.41 | $0.92 | −55% |
| Product | Revenue | Share |
|---|---|---|
| Liver Product | $148M | 80% |
| Heart Product | $33M | 18% |
| Lung Product | $2.3M | 1.2% |
| Service Unrelated To OCS Transplant | $1.0M | 0.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $184.6M (+9.7%)
Liver Product grew +28% year on yearLung Product -46% year on year
Segment Latestquarter on quarteryear on year
- Liver Product$148.0M$148.0Mquarter on quarter +6.5%year on year +28%+6.5%+28%
- Heart Product$33.4M$33.4Mquarter on quarter +29%year on year +3.8%+29%+3.8%
- Lung Product$2.3M$2.3Mquarter on quarter +2.5%year on year -46%+2.5%-46%
- Service Unrelated To OCS Transplant$1.0M$1.0Mquarter on quarter -23%year on year 0.00%-23%0.00%